NCT01391312View on ClinicalTrials.gov

Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

botulinum toxin Type A

botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.

DRUG

normal saline (placebo)

Normal saline (placebo) injected into the glabellar region on Day 0.

Trial Locations (1)

Unknown

East Chicago

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY